Company intelligence / Profile preview

Tritech Biopharmaceuticals Co., Ltd.

Ownership: Private
Development stage: Other

Overview

Tritech has developed a topical vardenafil gel (TR399) for erectile dysfunction that has completed a phase I/IIa trial with favorable results—side effect free, low Cmax, and long-lasting efficacy. Other pipeline programs are in preclinical or IND stages targeting pulmonary arterial hypertension, osteoporosis, insomnia, Raynaud syndrome, and hemangioma. The company specializes in non-invasive drug delivery using its proprietary screening platform to optimize transdermal formulations with improved safety profiles.[1][2][3][6]

Therapeutic areas: CardiovascularMen's HealthEndocrinologyRare DiseasesNeurology
Modalities: Small moleculesChemical drugsTopical/transdermal formulations[1][3][6]
Industry: Biotech

Drug pipeline

3 assets

TR563

Preclinical

2 more assets in the full pipeline.

Beyond the preview

Go deeper on Tritech Biopharmaceuticals Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tritech Biopharmaceuticals Co., Ltd..